Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel

TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia